Lenvatinib, quavonlimab, TRETINOIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, vibostolimab
MK-3475-02A
Phase 2 small_molecule active
Quick answer
Lenvatinib, quavonlimab, TRETINOIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, vibostolimab for PD-1 refractory melanoma is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- PD-1 refractory melanoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active